Global Elafibranor Market Outlook
Revenue, 2024
$766M
Forecast, 2034
$2.06B
CAGR, 2025 - 2034
10.4%
The Elafibranor industry revenue is expected to be around $845.3 million in 2025 and expected to showcase growth with 10.4% CAGR between 2025 and 2034. The pharmaceutical industry has witnessed a strong growth pattern of Elafibranor because of its expanding importance. The rising incidence of liver diseases especially non-alcoholic steatohepatitis and the lack of FDA-approved drugs for its treatment are the main drivers of this growth. The clinical trials currently underway and the expected approval of Elafibranor will transform NASH treatment options which demonstrates its enduring market value.
The dual PPAR/ agonist Elafibranor, also known as by its brand name Iqirvo, functions as a new therapeutic drug to treat metabolic disorders including NASH and 2 diabetes. The main features of Elafibranor include its anti-inflammatory and anti-fibrotic properties which help control liver fibrosis and inflammation. Elafibranor serves its primary function by treating NASH among other conditions which affect an increasing number of patients globally.
Market Key Insights
- The Elafibranor market is projected to grow from $765.7 million in 2024 to $2.06 billion in 2034. This represents a CAGR of 10.4%, reflecting rising demand across Non-Alcoholic Steatohepatitis Treatment, Type 2 Diabetes Management and Cardiovascular Disease Prevention.
- Genfit, Intercept Pharmaceuticals, Gilead Sciences are among the leading players in this market, shaping its competitive landscape.
- U.S. and Germany are the top markets within the Elafibranor market and are expected to observe the growth CAGR of 7.6% to 10.9% between 2024 and 2030.
- Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 10.0% to 13.0%.
- Transition like Advancements in Drug Development is expected to add $55 million to the Elafibranor market growth by 2030.
- The Elafibranor market is set to add $1.3 billion between 2024 and 2034, with manufacturer targeting Retail Pharmacies & Online Pharmacies Distribution Channels projected to gain a larger market share.
- With Rising prevalence of non-alcoholic steatohepatitis, and Advancements in drug discovery and development, Elafibranor market to expand 169% between 2024 and 2034.
Opportunities in the Elafibranor
Elafibranor demonstrates strong anti-fibrotic and anti-inflammatory properties which can also be improved through advanced drug delivery methods. Nanotechnology-based delivery systems enhance drug bioavailability and targeted delivery which could lead to better therapeutic results.
Growth Opportunities in North America and Europe
The United States together with North America represent a major market for Elafibranor. The drugs primary use in treating non-alcoholic steatohepatitis and 2 diabetes in this region drives its market demand. The regions pharmaceutical industry strength and research activities create high demand for Elafibranor. The market faces potential growth challenges because of alternative treatment options and therapeutic approaches. The market experiences growth because of improved drug delivery systems and rising healthcare spending and expanding knowledge about NASH and 2 diabetes.
The European market serves as a vital market for Elafibranor while Western Europe stands as its main demand center. The rising number of metabolic disorders and liver diseases together with the fast adoption of advanced therapeutics drives Elafibranor demand throughout this region. The market faces intense competition because pharmaceutical companies continue to develop new treatments. The European Elafibranor market expands because of rising research initiatives and positive government drug development policies and the established healthcare system.
Market Dynamics and Supply Chain
01
Driver: Rising Prevalence of Non-Alcoholic Steatohepatitis
The worldwide rise of NASH also represents a major opportunity for the Elafibranor market. The liver disease causes fat accumulation and inflammation which can also result in serious complications including cirrhosis and liver cancer. The dual PPAR/ agonist properties of Elafibranor make it an effective treatment for NASH which also drives its pharmaceutical market demand.
The advancement of technology in drug discovery and development has also enabled scientists to identify new therapeutic targets. Elafibranor also serves as an example of such advancements because it shows promise in treating metabolic disorders including 2 diabetes and dyslipidemia. The dual mechanism of action of the drug on PPAR and PPAR receptors provides a distinct therapeutic method for treating these conditions which also drives its market expansion.
02
Restraint: Regulatory Hurdles
The pharmaceutical industry operates under strict regulations which apply to Elafibranor as well. Elafibranor needs to pass through extensive clinical trials while fulfilling strict requirements for safety and effectiveness to obtain commercial approval. The drug faces significant market demand reduction because failing to meet these standards leads to expensive delays or complete rejection.
03
Opportunity: Expanding Therapeutic Applications and Strategic Collaborations for Market Penetration
The dual PPAR alpha and delta agonist Elafibranor exists mainly for treating non-alcoholic steatohepatitis. The drug has applications that go beyond its original purpose. The distinct mechanism of action of this drug enables its use for treating 2 diabetes and dyslipidemia in addition to its original application for non-alcoholic steatohepatitis thus creating new market opportunities.
Strategic partnerships between pharmaceutical companies and research institutions will help maximize Elafibranors market potential. The partnerships will help in conducting clinical trials, getting regulatory approvals faster and entering the market more efficiently, especially in regions with high prevalence of NASH and related metabolic disorders.
04
Challenge: High Development Costs
The development of new drugs like Elafibranor is an expensive process. It involves extensive research and development, clinical trials, and regulatory approval processes. These high costs can act as a significant barrier to entry, limiting the number of players in the market and potentially stifling innovation. Furthermore, these costs often get transferred to the end consumer, making the drug less affordable and potentially impacting market dynamics.
Supply Chain Landscape
1
Raw Material Suppliers
Sigma-AldrichFisher Scientific
2
Intermediate Product Manufacturers
GenfitInventiva
3
Final Product Manufacturers
Gilead SciencesIntercept Pharmaceuticals
4
End Users
HospitalsPharmaceutical CompaniesResearch Institutes
1
Raw Material Suppliers
Sigma-AldrichFisher Scientific
2
Intermediate Product Manufacturers
GenfitInventiva
3
Final Product Manufacturers
Gilead SciencesIntercept Pharmaceuticals
4
End Users
HospitalsPharmaceutical CompaniesResearch Institutes
Use Cases of Elafibranor in Non-Alcoholic Steatohepatitis Treatment & Type 2 Diabetes Management
Non-Alcoholic Steatohepatitis Treatment : The dual PPAR/ agonist Elafibranor serves as a primary medication for Non-Alcoholic Steatohepatitis treatment. The main therapeutic benefit of Elafibranor in this application stems from its anti-inflammatory and antifibrotic effects which help decrease liver inflammation and fibrosis. Genfit and Inventiva maintain their position as leading companies in this field through their innovative strategies and market dominance.
Type 2 Diabetes Management : Elafibranor is also used in managing 2 Diabetes. Its ability to improve insulin sensitivity and reduce blood glucose levels makes it a preferred choice in this application. Major players such as Novo Nordisk and Eli Lilly stand out in this application due to their extensive research and development efforts, and market dominance.
Cardiovascular Disease Prevention : The use of Elafibranor in the prevention of cardiovascular diseases is another significant application. Its lipid-modifying effects contribute to reducing cardiovascular risk in patients. Key players in this sector include Pfizer and AstraZeneca, recognized for their comprehensive cardiovascular portfolios and leading market positions.
Recent Developments
The pharmaceutical market has seen substantial growth from Iqirvo because it functions as a dual PPAR alpha and delta agonist. The drug stands as the leading treatment for non-alcoholic steatohepatitis because it has shown promising results in clinical trials despite the absence of FDA-approved medications for this condition.
December 2024 : Genfit Pharmaceuticals announced the successful completion of phase III clinical trials for Elafibranor, demonstrating significant improvements in patients with non-alcoholic steatohepatitis.
October 2024 : The partnership between Poxel Pharmaceuticals and Genfit focused on expanding Elafibranor distribution across Asian markets to combat the increasing NASH and PBC cases in the region.
July 2024 : Intercept Pharmaceuticals announced their research and development strategy now targets Elafibranor as a potential treatment for primary biliary cholangitis.
Impact of Industry Transitions on the Elafibranor Market
As a core segment of the Pharmaceutical industry,
the Elafibranor market develops in line with broader industry shifts.
Over recent years, transitions such as Advancements in Drug Development and Expansion into New Therapeutic Areas have redefined priorities
across the Pharmaceutical sector,
influencing how the Elafibranor market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Advancements in Drug Development
The pharmaceutical industry has made substantial progress in developing Elafibranor. The experimental drug Elafibranor was first developed to treat metabolic disorders Non-alcoholic Steatohepatitis and Primary Biliary Cholangitis and has produced encouraging results in clinical trials. The dual agonist mechanism of Elafibranor on Peroxisome Proliferator-Activated Receptors and has shown promise in decreasing inflammation and fibrosis which are essential for NASH and PBC progression. The pharmaceutical industry and healthcare sector have been affected by this transition because it provides a new therapeutic choice for diseases that have few available treatment options. This industry transition is expected to add $55 million in the industry revenue between 2024 and 2030.
02
Expansion into New Therapeutic Areas
Elafibranors potential is not only limited to metabolic disorders. Recent research has explored its application in the treatment of other diseases, including cardiovascular diseases and 2 diabetes. This transition has led to an expansion in the therapeutic areas covered by Elafibranor, opening new avenues for pharmaceutical companies and providing hope for patients suffering from these conditions.